Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Increases the protective effect of vaccines for multiple flu strains
Subscribe to our email newsletter
BioSante Pharmaceuticals has presented H1N1 vaccine results at the Immunotherapeutics & Vaccine Summit in Providence, RI. BioSante claims that its vaccine adjuvant – BioVant has increased the protective effect of vaccines for multiple flu strains, which resulted in 100% protection from symptoms of illness, including weight loss, and death in animal studies.
The BioSante presentation, BioVant Calcium Phosphate (CaP) Nanoparticles: An Effective & Safe Adjuvant for Influenza Vaccines including H1N1 and H5N1, showed that BioVant-adjuvant effectively enhanced the natural immune response to the swine flu, using a BioVant-adjuvanted matrix protein M1 vaccine, and to H5N1 (bird flu), using a BioVant-adjuvanted H5N1 vaccine delivered via intranasal administration.
Michael Snabes, vice president of clinical development at BioSante, said: “The results of the BioVant-influenza studies suggest that BioVant can increase the efficacy of a potential adjuvant-enhanced H1N1 vaccine. The exciting prospect is that BioVant also may allow use of lower doses of H1N1 swine flu vaccines in order to stretch potentially limited vaccine supplies.”